Payment overview · 2025
General Payments
$242.99
14 reported records · 8 companies
Healthcare provider profile · identity verified
Mirfat Bird, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · CAMDEN, AR · NPI 1225018518
Verified facts
What the public records show
CMS Open Payments records show Mirfat Bird, M.D. received $242.99 in general payments during 2025 across 14 reported records.
AstraZeneca Pharmaceuticals LP accounted for 41.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Caplyta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $99.70 | 41.0% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.41 | 15.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.50 | 9.3% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $21.88 | 9.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.18 | 7.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.79 | 6.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.36 | 5.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.17 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $242.99 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $99.70 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 62 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 186 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
62 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
186 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1176 | 163 |
| Atorvastatin Calcium | Atorvastatin Calcium | 847 | 206 |
| Gabapentin | Gabapentin | 777 | 159 |
| Levothyroxine Sodium | Levothyroxine Sodium | 605 | 133 |
| Losartan Potassium | Losartan Potassium | 542 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 523 | 119 |
| Pantoprazole Sodium | Pantoprazole Sodium | 520 | 123 |
| Metformin Hcl Er | Metformin Hcl | 510 | 137 |
| Tramadol Hcl | Tramadol Hcl | 483 | 78 |
| Lisinopril | Lisinopril | 477 | 115 |
| Omeprazole | Omeprazole | 473 | 107 |
| Furosemide | Furosemide | 467 | 107 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 414 | 90 |
| Metoprolol Tartrate | Metoprolol Tartrate | 336 | 59 |
| Buspirone Hcl | Buspirone Hcl | 326 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 318 | 75 |
| Trazodone Hcl | Trazodone Hcl | 310 | 71 |
| Sertraline Hcl | Sertraline Hcl | 309 | 60 |
| Carvedilol | Carvedilol | 305 | 63 |
| Potassium Chloride | Potassium Chloride | 304 | 67 |
| Tizanidine Hcl | Tizanidine Hcl | 298 | 76 |
| Oxycodone Hcl | Oxycodone Hcl | 286 | 29 |
| Eliquis | Apixaban | 268 | 41 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 262 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 249 | 72 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 241 | 52 |
| Alprazolam | Alprazolam | 234 | 36 |
| Simvastatin | Simvastatin | 232 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 226 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 218 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 208 | 60 |
| Spironolactone | Spironolactone | 205 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 203 | 47 |
| Allopurinol | Allopurinol | 192 | 42 |
| Montelukast Sodium | Montelukast Sodium | 186 | 37 |
| Ozempic | Semaglutide | 186 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 179 | 25 |
| Metformin Hcl | Metformin Hcl | 178 | 39 |
| Lorazepam | Lorazepam | 174 | 38 |
| Donepezil Hcl | Donepezil Hcl | 170 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 157 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 157 | 43 |
| Clonazepam | Clonazepam | 155 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 155 | 39 |
| Xarelto | Rivaroxaban | 152 | 23 |
| Famotidine | Famotidine | 149 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 145 | 37 |
| Pregabalin | Pregabalin | 143 | 23 |
| Methocarbamol | Methocarbamol | 141 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 140 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 133 | 33 |
| Mirtazapine | Mirtazapine | 133 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 129 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 125 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 121 | 33 |
| Topiramate | Topiramate | 119 | 23 |
| Bupropion Xl | Bupropion Hcl | 116 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 112 | 22 |
| Meloxicam | Meloxicam | 111 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 109 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 109 | 26 |
| Glimepiride | Glimepiride | 104 | 25 |
| Methylprednisolone | Methylprednisolone | 103 | 72 |
| Diclofenac Sodium | Diclofenac Sodium | 99 | 32 |
| Ondansetron Odt | Ondansetron | 97 | 32 |
| Ventolin Hfa | Albuterol Sulfate | 93 | 18 |
| Finasteride | Finasteride | 90 | 28 |
| Risperidone | Risperidone | 88 | suppressed |
| Prednisone | Prednisone | 87 | 25 |
| Promethazine Hcl | Promethazine Hcl | 85 | 13 |
| Azithromycin | Azithromycin | 83 | 72 |
| Irbesartan | Irbesartan | 83 | 24 |
| Atenolol | Atenolol | 74 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 74 | 16 |
| Glipizide | Glipizide | 73 | 14 |
| Fluconazole | Fluconazole | 72 | 41 |
| Diazepam | Diazepam | 70 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 70 | 11 |
| Trulicity | Dulaglutide | 70 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 69 | suppressed |
| Jardiance | Empagliflozin | 66 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 63 | 11 |
| Levetiracetam | Levetiracetam | 62 | 11 |
| Mounjaro | Tirzepatide | 62 | 11 |
| Clonidine Hcl | Clonidine Hcl | 61 | 13 |
| Memantine Hcl | Memantine Hcl | 60 | suppressed |
| Nystatin | Nystatin | 60 | 42 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 48 |
| Sucralfate | Sucralfate | 59 | 19 |
| Torsemide | Torsemide | 58 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 57 | 12 |
| Carbamazepine | Carbamazepine | 57 | suppressed |
| Nitroglycerin | Nitroglycerin | 57 | 31 |
| Warfarin Sodium | Warfarin Sodium | 55 | suppressed |
| Levofloxacin | Levofloxacin | 53 | 42 |
| Meclizine Hcl | Meclizine Hcl | 53 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 30 |
| Alendronate Sodium | Alendronate Sodium | 51 | 13 |
| Azelastine Hcl | Azelastine Hcl | 51 | 24 |
| Morphine Sulfate Er | Morphine Sulfate | 48 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 14 |
| Rizatriptan | Rizatriptan Benzoate | 43 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 42 | 16 |
| Temazepam | Temazepam | 42 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 37 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 37 | suppressed |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Baclofen | Baclofen | 36 | suppressed |
| Lactulose | Lactulose | 36 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 31 | 12 |
| Lithium Carbonate | Lithium Carbonate | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 29 | suppressed |
| Olanzapine | Olanzapine | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 16 |
| Estradiol | Estradiol | 27 | suppressed |
| Fentanyl | Fentanyl | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 16 |
| Ranolazine Er | Ranolazine | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 13 |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Primidone | Primidone | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Colchicine | Colchicine | 24 | 13 |
| Digoxin | Digoxin | 24 | suppressed |
| Methadone Hcl | Methadone Hcl | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 23 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 23 | suppressed |
| Movantik | Naloxegol Oxalate | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 19 |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Novolin R | Insulin Regular, Human | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 18 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | 11 |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 18 |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Zonisamide | Zonisamide | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Insulin Lispro | Insulin Lispro | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Admelog | Insulin Lispro | 16 | suppressed |
| Constulose | Lactulose | 16 | suppressed |
| Enulose | Lactulose | 16 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Perphenazine-Amitriptyline | Perphenazine/Amitriptyline Hcl | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Caplyta | Lumateperone Tosylate | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Estarylla | Norgestimate-Ethinyl Estradiol | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $242.99 · 14 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, CAPLYTA, EVENITY, MOUNJARO, Ozempic, Rybelsus, The Cologuard Plus Collection Kit, VRAYLAR, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error